Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.

Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer
Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led gains. Midcap and smallcap indices saw small gains.

Nifty could hit 27,000 once geopolitical tensions ease: Bajaj Finserv AMC CIO
Bajaj Finserv AMC CIO Nimesh Chandan projects 15% earnings growth for Nifty in FY28, with EPS rising to the ₹1,420–1,440 range, making valuations look attractive. He backs metals, construction, and cement as long-term plays on a global supply chain shift, holds gold and silver in the multi-asset portfolio, and flags El Niño and elevated US yields as key risks keeping Indian interest rates high in the near term.

Top Gainers & Losers on May 18: Gland Pharma, Coforge, PB Fintech, BSE, Voltas, Bharti Airtel among top gainers
Indian stocks marginally gained on May 18, driven by strong tech buying and pharma support, with Nifty 50 up 0.03% at 23,649 and BSE Sensex at 75,263. However, the broader market faced pressure as Nifty Midcap 100 and Nifty Smallcap 100 fell.

Market at Close | Bharti Airtel, Cipla lead rally as Sensex jumps 790 points, Nifty tops 23,650
The Sensex rose 790 points to close at 75,399, while the Nifty gained 277 points to settle at 23,690. The Nifty Bank index advanced 673 points to 54,129, and the Midcap index climbed 675 points to 60,840.
Vodafone Idea and 4 other midcap stocks hit 52-week highs, rally up to 40% in a month
Benchmark indices ended marginally higher as five BSE 150 Midcap stocks touched fresh 52-week highs, reflecting strong investor sentiment and bullish momentum. Vodafone Idea, SAIL, MCX, Laurus Labs and Ajanta Pharma recorded notable monthly gains, signalling sustained buying interest despite subdued broader market performance overall.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.